


## ASO and siRNA Therapeutics for CNS and Liver Disorders

**Nissan Chemical Corporation**, a forerunner in chemical innovations, is seeking novel **ASO and siRNA therapeutics for CNS and liver diseases**. They are especially interested in therapeutics that are facing **challenges with toxicity, stability, and efficacy**, which may be able to **leverage their proprietary platform** which incorporates 2'-O-[2-(N-methylcarbamoyl)ethyl] (MCE)-modified nucleotides to overcome these challenges.



### Approaches of Interest:

- Diseases of interest include **rare and neurodegenerative CNS diseases** (e.g. ALS, inherited ataxias), **rare metabolic and liver fibrosis diseases** (e.g. MASH, PBC, PSC), and **conditions caused by hepatocyte-secreted proteins** (e.g. complement-related disorders, hemophilia)
- Therapeutics for **CNS disorders could be delivered locally** (e.g. via intrathecal or intracerebroventricular injection) or systemically with BBB-penetrating technologies. For liver disorders, therapeutics should be administered systemically and **act within hepatocytes**.
- Therapeutics that work through **gene silencing** are highest priority
- Novel **gene and protein targets** for diseases of interest are in scope

### Out of Scope:

- Ultra-rare CNS and liver diseases (i.e. less than 1000 patients globally)
- Therapeutics that act via gene upregulation
- Other nucleic acid therapeutics (e.g. aptamers, miRNA)
- Novel chemically modified nucleic acid platforms

### Developmental Stages of Interest:

- Opportunities from basic research to late preclinical are in scope, provided there is *in vivo* proof of concept

### Submission Information and Opportunity for Collaboration

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Nissan Chemical Corporation is looking to establish research collaborations with partners who would be able to leverage their MCE-ASO/siRNA platform, which incorporates MCE-modified nucleotides. This unique chemistry is engineered to provide enhanced nuclease resistance, minimize hepatotoxicity and neurotoxicity, and improve knockdown efficacy and durability *in vivo*. They may also consider strategic investment.

### Opportunities sought

- Technologies
- Academics and expertise
- Centres of excellence
- Research projects
- Company profiles
- Biotech assets

### Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **5th March 2026 - 11:59 pm GMT**

### Have any questions?

Contact our team at [campaigns@inpart.io](mailto:campaigns@inpart.io)

